Asian Journal of Psychiatry
December 1, 2024
Hitesh Kumar Behera, Ramesh Joga, Sravani Yerram et al.
Psychedelic drug therapy has gained prominence for its potential in treating various mental health conditions, including depression, post-traumatic stress disorder (PTSD), and anxiety. Psychedelic treatment differs from conventional psychiatric approaches in mode of action, legal status, and treatment approach. This work delves into the therapeutic potential, mechanisms, and regulatory...
Current Psychiatry Reports
December 1, 2024
Daan de Jonge, Pim B. van der Meer, Cornelis Kramers et al.
2 citations
In this narrative review, we discuss evidence for psilocybin- and LSD-assisted treatment of alcohol use disorder (AUD) and major depressive disorder (MDD). We describe limitations of psychedelic research and posit methodological considerations when designing a trial in patients with both disorders. In AUD, a growing evidence base for psilocybin treatment shows a promising beneficial and...
Harm Reduction Journal
November 5, 2024
Chris Wilkins, Jose Romeo, Marta Rychert et al.
8 citations
The substitution of cannabis for alcohol and other drugs has been conceptualised in a harm reduction framework as where cannabis is used to reduce the negative side-effects, addiction potential, and social stigma of other drugs. There is currently mixed evidence with recent reviews suggesting cannabis co-use patterns may vary by age and ethnicity. Yet few studies have had large enough samples...
Pharmaceuticals
November 5, 2024
Tamara Valdez, Valbhi Patel, Nattaphone Senesombath et al.
4 citations
Psychedelics have recently (re)emerged as therapeutics of high potential for multiple mental health conditions, including substance use disorders (SUDs). Despite early mid-20th century anecdotal reports and pilot studies demonstrating the possibility of these substances in efficaciously treating conditions such as alcohol and opioid use disorders, legal restrictions and social stigma have...
Advanced Science
November 1, 2024
Wei Ren, Shan Yu, Kun Guo et al.
14 citations
Dogs interact with humans effectively and intimately. However, the neural underpinnings for such interspecies social communication are not understood. It is known that interbrain activity coupling, i.e., the synchronization of neural activity between individuals, represents the neural basis of social interactions. Here, previously unknown cross-species interbrain activity coupling in...
International Journal of Drug Policy
November 1, 2024
Rodolfo Olivieri, Luís Fernando Tófoli
1 citation
This essay examines the combination of psychoanalytic therapy and psychedelic substances in mid-20th century Argentina. Through document analysis, it examines the intersection of psychedelics and psychoanalysis, drawing from historical texts and writings by local psychoanalysts to develop a comprehensive understanding of the distinctive clinical practices and therapeutic approaches in the...
Current Topics in Behavioral Neurosciences
October 23, 2024
Grace Viljoen, Felix Betzler
5 citations
There is a large and rapidly growing body of literature investigating the therapeutic effects of classic psychedelics in affective and anxiety disorders, but very few studies have examined the inverse of this, that is, the potential for psychedelics to inflict anxiety and affective symptoms. A systematic literature search was performed and 39 papers were included in the final review to...
British Journal of Pharmacology
October 2, 2024
Ryan H. Gumpper, David E Nichols
9 citations
This brief review highlights some of the structure-activity relationships of classic serotonergic psychedelics. In particular, we discuss structural features of three chemotypes: phenethylamines, ergolines and certain tryptamines, which possess psychedelic activity in humans. Where they are known, we point out the underlying molecular mechanisms utilized by each of the three chemotypes of...
European Addiction Research
September 25, 2024
Ioanna A. Vamvakopoulou, David Nutt
13 citations
Background: Psychedelic substance use in ritualistic and ceremonial settings dates back as early as 8,500 BCE. Only in recent years, from the mid-20th century, we have seen the re-emergence of psychedelics in a therapeutic setting and more specifically for the treatment of addiction. This article aims to review research over the past 40 years using classic (psilocybin, lysergic acid...
Journal of Psychopharmacology
September 20, 2024
Abigail E. Calder, Benjamin Rausch, Matthias E. Liechti et al.
17 citations
Background: Psychedelic-assisted therapy (PAT) is permitted in Switzerland under its limited medical use program. Data from patients in this program represent a unique opportunity to analyze the real-world practice of PAT. Aims: This study compared the subjective effects of lysergic acid diethylamide (LSD) and psilocybin between patients undergoing PAT and healthy volunteers. For the patients,...